Premium
Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy
Author(s) -
Haddad N.,
Delyon J.,
Trabelsi Messai S.,
Herms F.,
Leccia M.T.,
Lebbe C.,
Whitney J.,
Bhatia S.,
BassetSeguin N.
Publication year - 2021
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19604
Subject(s) - ruxolitinib , medicine , malignancy , oncology , immune checkpoint , hematologic malignancy , dermatology , ipilimumab , immune system , immunotherapy , immunology , cancer , myelofibrosis , bone marrow
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom